Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism

Langenbeck's Archives of Surgery

Volumn 397, Issue 3, 2012, Pages 413-420

  Kovacevic, Bojan ^a   Ignjatovic, Mile ^a   Zivaljevic, Vladan ^a   Cuk, Vladimir ^a   Scepanovic, Milena ^a   Petrovic, Zaklina ^a   Paunovic, Ivan ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Calcimimetics; KDIGO; NKF K DOQI; Parathyroidectomy; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL SOCIETY; MINERAL METABOLISM; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REFERENCE VALUE; SECONDARY HYPERPARATHYROIDISM;

BONE AND BONES; CALCIUM; COMORBIDITY; GUIDELINE ADHERENCE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS;

EID: 84859852982     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-011-0901-9     Document Type: Article

References (26)

1. Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO4, CaxPO4 product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-8 (Pubitemid 32880350)
2. Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519-30
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-17
4. Kimata N, Albert JM, Akiba T et al (2007) Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan Dialysis Outcomes and Practice Patterns Study. Hemodial Int 11:340-8 (Pubitemid 46958589)
5. Young EW, Albert JM, Satayathum S et al (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67:1179-87 (Pubitemid 41623345)
6. National Kidney Foundation (2003) K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney 42:S1-S201
7. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ (2008) Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3:1423-1429
8. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT (2005) The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 46:925-932 (Pubitemid 41505468)
9. Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME (2004) Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 24:422-426 (Pubitemid 39279384)
10. Arenas MD, Alvarez-Ude F, Gil MT et al (2006) Application of NKF-K/DOQI clinical practice guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 21:1663-1668 (Pubitemid 43834646)
11. Block GA, Martin KJ, de Francisco AL et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-25 (Pubitemid 38477776)
12. Lindberg JS, Culleton B, Wong G et al (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800-7 (Pubitemid 41725117)
13. Ureña P, Jacobson SH, Zitt E et al (2009) Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study. Nephrol Dial Transplant 24:2852-9
14. Moe SM, Chertow GM, Coburn JW et al (2005) Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760-71 (Pubitemid 40139871)
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76(Suppl 113):S1-S130
16. Schneider R, Kolios G, Koch BM, Fernández ED, Bartsch DK, Schlosser K (2010) An economic comparison of surgical andmedical therapy in patients with secondary hyperparathyroidism - the German perspective. Surgery 148:1091-9
17. Narayan R, Perkins RM, Berbano EP et al (2007) Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 49:801-13 (Pubitemid 46802934)
18. Tominaga Y, Matsuoka S, Uno N, Sato T (2008) Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 12(Suppl 1):S21-S26
19. Mazzaferro S, Pasquali M, Farcomeni A et al (2008) Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant 23:2319-2323 (Pubitemid 351957582)
20. Gal-Moscovici A, Popovtzer MM (2005) New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 63:284-9 (Pubitemid 40542388)
21. Barreto FC, Barreto DV, Moysés RM et al (2008) K/DOQI - recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73:771-7 (Pubitemid 351323258)
22. Kestenbaum B, Andress DL, Schwartz SM et al (2004) Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66:2010-6
23. Dukkipati R, Kovesdy CP, Colman S et al (2010) Association of relatively low serum parathyroid hormone with malnutrition - inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr 20:243-54
24. Costa-Hong V, Jorgetti V, Gowdak LH, Moyses RM, Krieger EM, De Lima JJ (2007) Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 142:699-703 (Pubitemid 350018846)
25. Goldsmith DJ, Covic AA, Venning MC, Ackrill P (1997) Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 29:593-600
26. Coen G, Calabria S, Bellinghieri G et al (2001) Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron 88:149-55 (Pubitemid 32588869)